CRITICAL ELEMENTS

- Identification of Anatomical Structures for Level I and II Axillary Dissection
- Removal of Level III Nodes
- Removal of Rotter Nodes
- Removal of a Sufficient Number of Lymph Nodes for Axillary Staging
- Identification and Preservation of the Long Thoracic, Thoracodorsal, and Medial Pectoral Nerves
- Identification and Preservation of the Second and Third Intercostobrachial Nerves
- Drain Placement

1A. IDENTIFICATION OF ANATOMICAL STRUCTURES FOR LEVEL I AND II AXILLARY DISSECTION

Recommendation: Identification of the axillary vein and latissimus dorsi, pectoralis major, pectoralis minor, serratus anterior, and subscapularis muscles is essential for the resection of sufficient level I and II axillary nodes for breast cancer staging and adjuvant treatment planning.

Type of Data: Retrospective case series.

Strength of Recommendation: The consensus of the group supports this guideline based on historic evidence.

Rationale
Breast cancer typically spreads to the axillary lymph nodes first, and axillary dissection is important for both local control and treatment planning. The anatomic borders of the axilla must be identified to adequately resect level I and II axillary lymph nodes (see Fig. 3-1). The axilla is a triangular space that is delineated by the axillary vein.
superiorly, the latissimus dorsi muscle laterally, the serratus anterior muscle medially, the subscapularis muscle posteriorly, and the pectoralis minor and major muscles anteriorly. Lymph nodes in the axilla are identified by their location in one of three anatomical levels. Level I contains the axillary lymph nodes between the latissimus dorsi and the lateral border of the pectoralis minor muscle; level II contains the axillary lymph nodes between the lateral and medial borders of the pectoralis minor muscle; and level III encompasses the lymph nodes between the medial border of the pectoralis minor muscle and Halsted’s ligament. Level III axillary nodes can be exposed by resecting or dividing the pectoralis minor muscle. Axillary lymph nodes are located primarily in level I (60% to 70% of nodes), followed by level II (20% to 30%) and level III (10% to 20%). Axillary metastases are most often identified in level I nodes followed by level II nodes. Single-node metastasis occurs in level I nodes almost exclusively. Metastases that occur in level II or III nodes in the absence of level I metastasis (“skip” metastases) are rare and typically occur in level II nodes.

1B. REMOVAL OF LEVEL III NODES

**Recommendation:** The removal of level III axillary nodes is not typically indicated for patients with stage I or II breast cancer but should be considered to facilitate local disease control in patients with locally advanced breast cancer or N2 disease and patients in whom the nodes are identified by palpation intraoperatively.
**Sentinel Lymphadenectomy**

**CRITICAL ELEMENTS**
- Identification of All Sentinel Nodes
- Technique for Injecting Localizing Tracer or Dye
- Preincision Evaluation of Drainage Pattern
- Node Removal Technique to Limit Seroma Formation

1. **IDENTIFICATION OF ALL SENTINEL NODES**

**Recommendation:** All sentinel nodes must be identified, removed, and subjected to pathologic analysis to ensure that sentinel lymph node mapping and sentinel lymphadenectomy provide accurate information for breast cancer staging. Sentinel nodes are defined by the presence of a tracer (radioactive tracer and/or colored dye) that has been previously injected into the affected breast or by the presence of a dominant palpable lymph node identified by the operating surgeon.

**Type of Data:** Randomized multicenter prospective trials.

**Strength of Recommendation:** The group strongly endorses this recommendation based on strong evidence.

**Rationale**
The original definition of a sentinel lymph node was “the first draining lymph node on the direct pathway from the primary tumor site.”¹ According to the sentinel node hypothesis, tumor cells migrate from a primary tumor focus to the first draining lymph node(s) before involving distal lymph nodes. Sentinel lymph nodes are variably located but are usually within the level I or II axilla near the lateral thoracic vein.²,³ The median number of sentinel nodes removed during a sentinel lymphadenectomy is between two and three; in the two largest randomized clinical trials comparing sentinel...
lymphadenectomy to axillary node dissection, the mean numbers of sentinel nodes removed per procedure were 2.8 in the National Surgical Adjuvant Breast and Bowel Project B32 trial and 2.2 in the ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance) trial. For cases in which only one sentinel lymph node is removed, the reported false negative rate of the procedure is greater than 10%, potentially leading to the assignment of lower than actual disease stages to some breast cancers.

### Identification Using a Radioactive Tracer

Most commonly technetium sulfur colloid is injected in the breast an hour prior to the planned sentinel node biopsy, but the tracer can be injected the day before if more convenient. After the patient is under general anesthesia, a handheld gamma detection probe is held over the axilla to identify the area of greatest radioactivity. A 3- to 6-cm incision is then made near the area of greatest radioactivity within the region at the base of the axillary hairline. The clavipectoral fascia is opened to the level I axilla, and the area around the lateral thoracic vein and second intercostobrachial nerve is evaluated using the gamma detection probe. The first sentinel node is the node with the highest absolute radioactivity count. The nodes are excised using clip, tie, or sealing device closure of the indwelling lymphatics and vessels, and blunt dissection of the surrounding fat is performed to prevent the removal of multiple nonsentinel nodes. After the first sentinel node is excised, its ex vivo highest or 10-second radioactive count is obtained and recorded, and the radioactivity of the axillary basin is reassessed. All nodes whose radioactive count is at least 10% that of the most radioactive node are considered sentinel nodes and are removed in a similar fashion, and ex vivo radioactive counts are recorded for each node. Confirmation of an elevated ex vivo count of the node ensures that it is indeed a hot node and not that the count was falsely elevated in vivo due to scatter from the primary injection in the breast.

### Identification Using Vital Blue (or Colored) Dye

For sentinel node identification with a blue dye, isosulfan or methylene blue are most commonly used. The dye is injected in the breast and massaged; subsequently, the axilla is incised and opened as described for sentinel node identification with a radioactive tracer. Blunt dissection is performed to identify the dye-filled lymphatic tract. This tract is then followed proximally and distally until a blue-stained sentinel node is identified (Fig. 4-1). If more than one dye-filled lymphatic tract is identified, each is followed until a blue node is identified. Blue-stained sentinel nodes are removed in a fashion similar to that used to remove sentinel nodes identified using a radioactive tracer. Another colored tracer in current use is indocyanine green; in cases in which this tracer is used, all nodes with fluorescent tracer uptake must be identified.

### Identification Using a Dual-Tracer Approach

The majority of sentinel lymphadenectomy procedures utilize a dual-tracer technique. If both a radioactive tracer and blue dye have been injected, nodes that are
radioactive and/or stained blue are considered sentinel nodes. All blue-stained nodes should be assessed with a gamma detection probe for radioactivity, and all radioactive nodes that are removed should be assessed for the presence of blue dye. Some nodes may only be identified by one modality, as studies show that the procedure is the most accurate when dual tracer technique is utilized.⁶

Identification Using Palpation of the Axilla
As a component of sentinel lymphadenectomy, careful palpation of the level I and II axilla is essential to guiding the complete removal of all sentinel nodes. Nodes that feel abnormal on palpation should be categorized as sentinel nodes and removed regardless of whether they are radioactive or stained blue.⁷

2. TECHNIQUE FOR INJECTING LOCALIZING TRACER OR DYE

Recommendation: The site of localizing tracer or dye injection within the affected breast and/or subareolar plexus does not influence the identification of the axillary sentinel node(s).

Type of Data: Multiple single institutional series, small prospective randomized study, and systematic review.

Strength of Recommendation: Consensus of the group is that the evidence is strong.

Rationale
Over the past 15 years, several different techniques and combinations of techniques have been employed for the injection of radioactive tracer and/or dye for sentinel node identification. Pesek et al⁵ published the most comprehensive and systematic...